Recent Events - The arbitration case between the company's subsidiary REGEN and Datoo regarding the agency rights for the AestheFill product is still under review. On January 30, 2026, the Shenzhen International Arbitration Court revoked the previous temporary sales restriction on REGEN, but the final outcome of the case has not yet been announced, which may impact the company's future business layout [2]. Business Development - The company is accelerating its diversification efforts, with the anti-hair loss product Minoxidil having obtained a drug registration certificate and is advancing in market promotion. The bone structure beauty filler product "Gekela" has received positive market feedback. These new products may become future growth points, although specific sales targets have not been publicly disclosed [3]. Financial Performance - In the first three quarters of 2025, the company reported revenue of 1.865 billion yuan and a net profit attributable to shareholders of 1.093 billion yuan, representing year-on-year declines of 21.49% and 31.05%, respectively. The gross profit margin remains high at 93.36%. The ongoing pressure on performance is attributed to intensified industry competition [4]. Stock and Capital Performance - Recent stock price fluctuations have been significant, with two large block trades occurring on February 3, 2026, at a transaction price of 113 yuan per share, reflecting a discount of 23.43%. On February 5, the stock price increased by 5.09% to 155.87 yuan per share. The flow of funds and changes in institutional holdings may reflect market sentiment [5].